The Medical Psilocybin Advisory Board, led by its Research and Continuous Improvement Committee under the chairmanship of Dan Jennings, gathered recently to discuss regulatory advancements, ongoing education, and interdisciplinary collaboration for psilocybin applications in New Mexico. The virtual meeting, hosted by Dominic Zerlow, Director of the Center for Medical Cannabis and Psilocybin, marked another step forward in the state’s effort to craft a sustainable and evidence-based medical psilocybin program.

Rulemaking Updates and Public Participation

One of the significant agenda items was an update on the proposed rules for psilocybin regulation. According to Dominic Zerlow, the rule hearing for these initial regulations has been scheduled for April 24, 2026. These regulations will address key areas such as cultivation and testing standards, laying the groundwork for a comprehensive legal framework. Interested parties have been encouraged to read the draft rules on the program’s website and submit their comments via email to the Department of Health’s legal team to ensure public records are maintained appropriately.

While committee meetings allow for open discussion, Zerlow clarified that public comments made during these meetings will not be considered formal feedback for regulatory purposes. For that, stakeholders must submit their input through the specified email channel. The distinction underscores the importance of engaging with the official rulemaking process to ensure that diverse voices contribute to policy refinement.

In addition to the rule hearing, Zerlow noted several other upcoming events. These include a propagation-focused meeting on April 16, as well as hybrid meetings on equitable access and cultural considerations scheduled for later in the month. Training and education sessions are also in the pipeline, reflecting the program’s commitment to preparing stakeholders for the operational realities of psilocybin treatment.

Interdisciplinary Expertise Drives Collaboration

The meeting showcased input from multiple stakeholders and experts who bring unique perspectives to the table. Among them were health educators, legal experts, medical practitioners, and veterans' advocates. Dominic Zerlow introduced several key figures within the Department of Health, such as Dr. Robert Truckner, the medical director, and Jorge Gonzalez, the psilocybin program manager.

Volunteer introductions followed, reflecting the diverse expertise participating in the program's development. For example, Dr. Lydia Fatemi, founder of the Conscious Physician Psychedelics Academy, highlighted her efforts to educate healthcare providers on psilocybin use. Similarly, Kate Hawk, with decades of experience in trauma therapy, noted her ongoing participation in FDA trials studying psychedelic therapies.

The meeting also included contributions from legal professionals like Sam Wolfe, independent researchers such as Gregory Evans, and nonprofit representatives like James Brown of the 5° N Healing Foundation, which supports veterans and first responders dealing with PTSD. These introductions underscored the broad coalition working to shape New Mexico’s psilocybin program.

Ongoing Projects and Intersectional Work

The heart of the session lay in discussions about three ongoing project areas: challenging and adverse experiences, emergency preparedness, and patient and community education. Each of these themes was assigned to interdisciplinary working groups tasked with presenting updates and gathering feedback.

1. Challenging and Adverse Experiences

This group, led by James Brown, aims to develop guidelines and protocols to address potential negative experiences during psilocybin use. While no firm proposals were finalized during the meeting, the presentation highlighted the importance of preparation, mitigation strategies, and a robust reporting framework to ensure patient safety.

2. Emergency Preparedness

Gregory Evans and Danielle Leonard reported on protocols to address emergencies during psilocybin therapy sessions. This includes defining what constitutes an emergency, establishing clear escalation procedures, and ensuring facilitators and support staff are well-trained to manage crises.

3. Patient and Community Education

Education remains a cornerstone of the program. Brenda Burgard, chair of the training and education subcommittee, emphasized the need for robust training to prepare healthcare providers and community members for the unique aspects of psilocybin therapy. She expressed optimism about the progress being made, inviting stakeholders to attend an afternoon session for more detailed discussions.

Encouraging Participation and Feedback

Throughout the meeting, participants were encouraged to engage actively, whether by asking questions in the chat box or contributing directly during discussion periods. Dominic Zerlow emphasized the importance of a respectful and constructive tone, reminding attendees to target their critiques at ideas rather than individuals.

The session provided a valuable platform for exchanging ideas, but as Zerlow and Jennings pointed out, no decisions were made during the meeting. Instead, the committee will compile the insights gathered for further review and potential integration into broader policy discussions.

What’s Next for New Mexico’s Psilocybin Program?

As New Mexico continues to position itself as a leader in medical psilocybin, the Research and Continuous Improvement Committee is laying essential groundwork. The upcoming rule hearing on April 24 represents a critical milestone, potentially setting precedents for other states exploring similar initiatives.

Meanwhile, the focus on equity, safety, and education ensures that the program remains inclusive and science-driven. With working groups diving into intersectional challenges and a robust regulatory framework taking shape, New Mexico stands to establish a model that could influence psilocybin adoption nationwide. Stakeholders are encouraged to participate in upcoming meetings, engage with public comment opportunities, and contribute to this evolving conversation.

For those looking to stay informed or get involved, resources and registration links for future sessions can be found on the psilocybin program’s official website. With discussions around cultivation standards, patient education, and emergency protocols intensifying, now is the time for professionals, advocates, and the broader community to make their voices heard.